Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dulanermin + FOLFOX + bevacizumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of **dulanermin** (a recombinant human Apo2L/TRAIL that induces apoptosis in tumor cells), **FOLFOX** (a chemotherapy combination of folinic acid, fluorouracil, and oxaliplatin used primarily for colorectal cancer), and **bevacizumab** (a humanized monoclonal antibody targeting vascular endothelial growth factor A/VEGF-A, inhibiting angiogenesis). This investigational combination targets malignant cells through multiple antineoplastic mechanisms: direct apoptosis induction (dulanermin), cytotoxic chemotherapy (FOLFOX), and angiogenesis inhibition (bevacizumab). FOLFOX is most often used intravenously as cycles for 12-24 weeks in metastatic or advanced colorectal carcinoma; bevacizumab is used IV as an adjunct to chemotherapy in several cancers including colorectal cancer.
- Other names
- folinic acid + fluorouracil + oxaliplatin + dulanermin + bevacizumab
02
Targets
DNATNFRSF10A (Death receptor 4)TNFRSF10B (DR5)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on dulanermin + FOLFOX + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dulanermin + FOLFOX + bevacizumab.